Book contents
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- 10 HER
- 11 The insulin–insulin-like growth-factor receptor family as a therapeutic target in oncology
- 12 TGF-β signaling in stem cells and tumorigenesis
- 13 Platelet-derived growth factor
- 14 FMS-related tyrosine kinase 3
- 15 ALK: Anaplastic lymphoma kinase
- 16 The FGF signaling axis in prostate tumorigenesis
- 17 Hepatocyte growth factor/Met signaling in cancer
- 18 PI3K
- 19 Intra-cellular tyrosine kinase
- 20 WNT signaling in neoplasia
- 21 Ras
- 22 BRAF mutations in human cancer: biologic and therapeutic implications
- 23 Aurora kinases in cancer: an opportunity for targeted therapy
- 24 14-3-3 proteins in cancer
- 25 STAT signaling as a molecular target for cancer therapy
- 26 The MYC oncogene family in human cancer
- 27 Jun proteins and AP-1 in tumorigenesis
- 28 Forkhead box proteins: the tuning forks in cancer development and treatment
- 29 NF-κB and cancer
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- Index
- References
28 - Forkhead box proteins: the tuning forks in cancer development and treatment
from Part 2.1 - Molecular pathways underlying carcinogenesis: signal transduction
Published online by Cambridge University Press: 05 February 2015
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- 10 HER
- 11 The insulin–insulin-like growth-factor receptor family as a therapeutic target in oncology
- 12 TGF-β signaling in stem cells and tumorigenesis
- 13 Platelet-derived growth factor
- 14 FMS-related tyrosine kinase 3
- 15 ALK: Anaplastic lymphoma kinase
- 16 The FGF signaling axis in prostate tumorigenesis
- 17 Hepatocyte growth factor/Met signaling in cancer
- 18 PI3K
- 19 Intra-cellular tyrosine kinase
- 20 WNT signaling in neoplasia
- 21 Ras
- 22 BRAF mutations in human cancer: biologic and therapeutic implications
- 23 Aurora kinases in cancer: an opportunity for targeted therapy
- 24 14-3-3 proteins in cancer
- 25 STAT signaling as a molecular target for cancer therapy
- 26 The MYC oncogene family in human cancer
- 27 Jun proteins and AP-1 in tumorigenesis
- 28 Forkhead box proteins: the tuning forks in cancer development and treatment
- 29 NF-κB and cancer
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- Index
- References
Summary
Introduction
Forkhead box (Fox) proteins belong to a superfamily of transcription factors that is characterized by a highly conserved “winged-helix” DNA-binding domain. Following the discovery of the first Fox transcription factor, FoxA, in Drosophila melanogaster, the identification of Fox genes has hitherto revealed at least 19 subclasses in humans (1). Fox proteins hold tight reins on determining cell fate, in particular cell proliferation, differentiation, and survival; thus it is predictable that the deregulation of these proteins has a major impact in the pathogenesis of cancer. Of the Fox proteins, the subfamilies FoxO, FoxM, FoxP, FoxC, and FoxA have been shown to participate in oncogenesis (2). As these Fox proteins recognize similar promoter elements on genomic DNA, they can potentially regulate the expression of overlapping gene targets. However, this chapter will focus on the involvement of the FoxO and FoxM1 proteins in cancer as there is an increasingly well-established and strong relationship between these two groups of Fox proteins through early tumorigenesis to advanced cancer progression and even chemotherapy response.
An overview of FoxO and FoxM1
The mammalian FoxO proteins, FoxO1, FoxO3a, FoxO4, and FoxO6, are downstream effectors of the PI3K-Akt (also called PKB) signaling pathway, a signaling cascade that is a focal point for deregulation in most cancers (3). The subcellular localization of FoxO, with the exception of the constitutively nuclear FoxO6, is typically dependent on the phosphorylation of these FoxO proteins by several key kinases, namely Akt/PKB, serum glucocorticord-induced protein kinase (SGK), CK1, IκB kinase (IKKβ), C-Jun N-terminal kinase (JNK), and p38 MAPK (4,5). It is well established that Akt-mediated phosphorylation of FoxO proteins results in cytoplasmic relocation and the consequent inability of these proteins to initiate transcription. Upon translocation to the nucleus, activated FoxO proteins are able to control cell fate by transcriptionally activating or repressing target genes by binding to the DNA of consensus sequences, and by interacting with other transcriptional co-activators such as p300/CREB-binding protein (CBP).
- Type
- Chapter
- Information
- Molecular OncologyCauses of Cancer and Targets for Treatment, pp. 328 - 335Publisher: Cambridge University PressPrint publication year: 2013